Business Wire

Case Study: Durham University Deploys Liqid Composable Infrastructure to Study Universe’s 14 Billion-Year History with Adaptive, More Sustainable Infrastructure

Share

LIQID Inc., one of the world’s leading software companies delivering data center composability, announced today a new case study with Durham University in Durham, England, describing its deployment of Liqid composable disaggregated infrastructure (CDI) software. Durham University is home to the COSmology MAchine (COSMA) operated by the Institute for Computational Cosmology (ICC) and is a national supercomputing facility that is part of the UK’s Distributed Research utilizing Advanced Computing (DiRAC) system. Liqid Matrix™ CDI software is part of a system used to study the origins of the universe, composing disaggregated GPUs in a tight footprint designed for a more sustainable digital architecture. With the ability to grow as resources are needed, the Liqid system will help researchers in the UK and around the world unlock the mysteries of the 14 billion-year history of the cosmos with far greater speed and efficiency than traditional data center systems.

“We are honored to work with institutions like Durham University and COSMA researchers to provide the resources to better explore the most profound questions in science,” said Sumit Puri, CEO & Cofounder, Liqid. “By providing the kind of software-defined data performance and architectural flexibility for powerful GPU, Liqid is enabling research breakthroughs that would have been impossible with traditional, static data center architectures so scientists can focus on results instead of waiting for resources and performance to become available.”

Liqid Matrix CDI Delivers Big Bang for Cosmologists with Adaptive, Efficient Architecture

“Durham University is using cutting-edge CDI to accelerate research, improve resource utilization, and reduce the university’s carbon footprint,” said Alistair Basden, technical manager for the DiRAC Memory Intensive Service at Durham University, who was interviewed for the case study entitled Durham University’s Institute for Computational Cosmology Accelerates Results with Composability from Liqid.

The COSMA memory-intensive system is designed specifically to support the largest cosmological simulations, most notably running simulations starting with the Big Bang and propagating through the entire history of the universe. Each simulation of dark matter, dark energy, black holes, galaxies and other structures in the universe often takes months to run, followed by long periods of data analysis.

While all of the applications deployed by DiRAC are memory intensive, valuable GPU resources are required for some of its most challenging simulations and analysis. Durham University chose Liqid Matrix software-based composable system in order to be able to share and scale GPUs in the exact amounts required for any given workload. Once the workload has been completed, GPU resources can be redistributed through Liqid Matrix software for use by other applications.

“It would be wasteful for us to populate all our nodes with GPUs,” Basden said in an interview for the case study. “Instead, we have some fat compute nodes and a login node, and we’re able to move GPUs between those systems. Composing our GPUs gives us flexibility with a smaller number of GPUs. We can individually populate the servers with one or more GPUs as required at the click of a button.”

Durham University IT is also deploying Liqid Matrix-based systems as an element of its overall strategy for a more sustainable IT ecosystem. Software-based composability enables users to do more with less, increasing efficiency and curtailing the need for physical space to store the hardware while providing significant reductions in cooling and water requirements.

“Rather than populating all our servers with GPUs, we can compose the resources we need to each server. That reduces our carbon footprint,” said Basden.

To learn more about Liqid’s academic deployments, review Liqid’s case study outlining the company’s work with the University of Illinois at Chicago’s Electronic Visualization Laboratory. Schedule an appointment with an expert on solutions based on Liqid Matrix ™ CDI software-based and set up a free infrastructure evaluation by going here. Follow Liqid on Twitter and LinkedIn to stay up to date with the latest Liqid news and industry insights.

About Liqid Inc.

Liqid’s composable infrastructure software platform, Liqid Matrix ™, unlocks cloud-like speed and flexibility plus higher efficiency from on-prem infrastructure. Now IT professionals can configure, deploy, and scale physical, bare-metal servers in seconds, then reallocate valuable accelerator and storage resources via software as needs evolve. Dynamically provision previously impossible systems or scale existing investments, and then redeploy resources where needed in real-time. Unlock cloud-like datacenter agility at any scale and experience new levels of resource and operational efficiency with Liqid.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Robert Brumfield
Sr. Director, Global Communications
Liqid Inc.
917 224 7769
brumfield.bob@liqid.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Teva Announces Promising Interim Results From Its Study PEARL, About the Impact of AJOVY ® (fremanezumab)24.6.2022 18:54:00 CEST | Press release

Teva Pharmaceuticals Europe B.V. today announces promising interim results from its Pan-European Real World study (PEARL), presented for the first time at the European Academy of Neurology (EAN) Congress in Vienna, Austria. The two-year Pan-European Real World (PEARL) prospective, observational study of AJOVY® (fremanezumab), looks at its effectiveness in patients with chronic migraine or episodic migraine, and is an ongoing study sponsored by Teva Pharmaceuticals Europe BV.1 These findings further offer insight into the treatment of migraine in real-world clinical practice. The interim findings were presented by Faisal Mohammad Amin, Associate Professor of Neurology at the University of Copenhagen, Denmark. Out of the total planned 1100 patients in PEARL, 389 patients are included in the interim analysis presented. These findings show that 54.7% of patients in the study had their monthly-migraine-days reduced by 50% or more, over the six-month period from the start of treatment. Addit

Brigade-M3 European Acquisition Corp. 2021 Annual Report24.6.2022 16:59:00 CEST | Press release

Brigade-M3 European Acquisition Corp. (the “Company”), a special purpose acquisition company that was incorporated on 21 April 2021 under the laws of the Cayman Islands as an exempted company with limited liability and is listed on Euronext Amsterdam, today published its annual report for the period 21 April 2021 to 31 December 2021. The full report can be downloaded from the Company’s website via the following link: https://www.brigadem3eac.com/documents IMPORTANT INFORMATION This press release contains information that qualifies as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation. DISCLAIMER This announcement is not for distribution or release, directly or indirectly, and should not be distributed in or sent into, the United States, Australia, Canada, Japan, the Cayman Islands or South Africa or any other jurisdiction in which such distribution or release would be unlawful or would require registration or other measures. This announcement does n

PUMA Kicks Off Its Largest Web3 Collaboration To Date, with 10KTF Shop24.6.2022 16:41:00 CEST | Press release

PUMA has entered New Tokyo, the virtual city 10KTF calls home. The shop is known for its streetwear offerings and is owned by Wagmi-san, a digital artisan whose collections and NFT community recently welcomed the global sports brand. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220624005314/en/ PUMA Kicks Off Its Largest Web3 Collaboration To Date, with 10KTF Shop PUMA has entered New Tokyo, the virtual city 10KTF calls home. The shop is known for its streetwear offerings and is owned by Wagmi-san, a digital artisan whose collections and NFT community recently welcomed the global sports brand. (Photo: Business Wire) News of the partnership was shared at an event hosted by 10KTF last night in New York. Their event was one of many hosted during the week of NFT.NYC, a conference attended by crypto industry professionals, traders, and other web3 enthusiasts. The official announcement confirms weeks of speculation after PUMA tw

Suzano outlines ESG milestone achievements and commitments at second annual ESG call24.6.2022 16:14:00 CEST | Press release

Suzano, the world’s largest hardwood pulp producer, today held its second annual ESG Call centered around its ambition to be a ‘regenerative company for a regenerative society’. Today’s ESG Call spotlighted measurable progress and ambitions across three core areas of action: climate change, biodiversity and social development. On Climate Change, the ACT initiative of the French Government and CDP scored Suzano ahead of its pulp and paper industry peers in virtually every metric. In 2021, Suzano brought forward its target for removing 40 million tons of carbon dioxide from the atmosphere from 2030 to 2025 which is being achieved through improvements to its industrial processes, such as systematically replacing the use of fossil fuels at its industrial plants with biomass, and through conversion of degraded land. As part of the company’s social commitments, Suzano launched a target in 2020 to lift 200,000 people out of poverty. This is more than pertinent, given that in Brazil, 10% of th

Kyowa Kirin Receives Positive CHMP Opinion for Use of CRYSVITA ® ▼ (burosumab) for the Treatment of Tumour-Induced Osteomalacia (TIO)24.6.2022 15:38:00 CEST | Press release

Kyowa Kirin Co., Ltd. (TSE: 4151, Kyowa Kirin) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended that CRYSVITA® (burosumab) be approved for the treatment of FGF23-related hypophosphataemia in Tumour-Induced Osteomalacia (TIO) associated with phosphaturic mesenchymal tumours (PMTs) that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.1 CRYSVITA is also already licensed for use in the rare disease X-Linked Hypophosphataemia (XLH), for children and adolescents between 1 and 17 years of age with radiographic evidence of bone disease, and in adults.2 Also known as oncogenic osteomalacia, TIO is an acquired disorder caused by typically small, slow-growing, benign PMTs.3,4 It is a rare condition with less than 1000 cases reported in the medical literature,4 which mainly affects adults and with a mean onset age of 40 – 45 years.3,5 TIO is associated with p

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom